If you missed the MAP 2024 conference, here's some of our highlights 👇
💉 MAP 2024 nicely summarised recent discoveries in precision medicine, technologies for cancer profiling, and biomarker-driven development of targeted therapeutics. But it omitted advances in proteomics - where there has been notable progress. We would welcome the opportunity to showcase this next year!
🤖 Important topics/challenges discussed in this session included: ethical and privacy concerns; integration with current IT-systems; data availability; what is appropriate clinical validation; and the extent of user guidance/ training required for proper-use. All big challenges as AI rapidly approaches the clinic
🗺️ The programme nicely built up to the ‘RoadMAP to the clinic’ session, which focused on new AI-based developments and their implementation in clinical practice. The main take home was that while there are some great exemplars of AI in the clinic, it’s important to support its success with the necessary infrastructure
Congratulations to ESMO - European Society for Medical Oncology for putting on such an inspiring event, full of discussions and guidance on the use of AI for drug development and clinical practice. We look forward to returning next year!
Photo credit - MAP2024
#MAP2024 #precisionmedicine #diagnostics #clinicaltrials #clinicaloncology #AI #kinomica
Head Translational Medicine & Diagnostics at Nucleai. Associate Editor of the journal Artificial Intelligence in Precision Oncology. I am a Dad, an Ironman, and support the Kyle Pease foundation.
7moThanks Jennifer!!! I really enjoyed the discussion!!!